Review of Clinical Trials in COVID-19: Trying to Solve the Clinicians’ Conundrum
SARS-CoV-2 and the resulting “COVID-19” has escalated into a pandemic and has resulted in significant morbidity and mortality. Currently, there is no approved antiviral treatment available. Few antiviral agents are undergoing clinical trials for their safety and efficacy against COVID-19. With various repurposed drugs under evaluation, treatment approaches range from search for an effective antiviral, immunomodulation and anticoagulation, use of point-of-care ultrasound to novel ventilatory strategies. Newer agents targeting the inflammatory pathway are also under investigation. There are more than 1955 ongoing clinical trials of repurposed and novel agents. Here we review some of the ongoing trials that have published, at least, interim results of treating patients with COVID-19.
KeywordsCOVID-19 - Remdesivir - Favipiravir - Lopinavir/Ritonavir - immunomodulators - convalescent plasma
23 July 2020 (online)
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Jin Y, Yang H, Ji W. et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020; 12 (04) E372
- 2 WHO. Modes of Transmission of Virus Causing COVID-19: Implications for IPC Precaution Recommendations. Available at: https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution- recommendations. Accessed May 7, 2020
- 3 MyGov. COVID-19 Dashboard. Available at: https://www.mygov.in/covid-19. Accessed May 7, 2020
- 4 Bi Q, Wu Y, Mei S. et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis 2020; DOI: 10.1016/S1473-3099(20)30287-5.
- 5 Lauer SA, Grantz KH, Bi Q. et al. The incubation period of Coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172 (09) 577-582
- 6 Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic Coronavirus disease 2019 (COVID-19). Cureus 2020; 12 (04) e7560
- 7 Vetter P, Vu DL, L’Huillier AG, Schibler M, Kaiser L, Jacquerioz F. Clinical features of covid-19. BMJ 2020; 369: m1470
- 8 MOHFW. Revised Guidelines on Clinical Management of COVID –19. Available at:https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCO VID1931032020.pdf. Accessed June 6, 2020
- 9 Wang Y, Zhang D, Du G. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395 (10236) 1569-1578
- 10 Grein J, Ohmagari N, Shin D. et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMoa2007016.
- 11 Business Wire. Gilead Announces results from phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19. Available at: https://www.businesswire.com/news/home/20200429005424/en/. Accessed June 6, 2020
- 12 Cai Q, Yang M, Liu D. et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020; DOI: 10.1016/j.eng.2020.03.007.
- 13 Young BE, Ong SWX, Kalimuddin S. et al. Singapore 2019 Novel Coronavirus Outbreak Research Team. epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020; DOI: 10.1001/jama.2020.3204.
- 14 Cao B, Wang Y, Wen D. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382 (19) 1787-1799
- 15 Hung IF-N, Lung K-C, Tso EY-K. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020; 395 (10238) 1695-1704
- 16 Haematology TL. The Lancet Haematology. The resurgence of convalescent plasma therapy. Lancet Haematol 2020; 7 (05) e353
- 17 Lim J, Jeon S, Shin HY. et al. Case of the index patient who caused tertiary transmission of COVID-19 Infection in Korea: the application of lopinavir/ritonavir for the treatment of covid-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020; 35 (06) e79
- 18 Gautret P, Lagier JC, Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID - results of an open - label non - randomized clinical trial. Int J Antimicrob Agents 2020; DOI: 10.1016/j.ijantimicag.2020.105949.
- 19 Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?. Antiviral Res 2012; 95 (03) 202-206
- 20 Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787
- 21 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18 (05) 1094-1099
- 22 Paranjpe I, Fuster V, Lala A. et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020; DOI: 10.1016/j.jacc.2020.05.001.
- 23 Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta- analysis. medRxiv 2020; DOI: 10.1101/2020.03.30.20048058.
- 24 Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apheresis Sci 2020; 59 (03) 102790
- 25 Gattinoni L, Chiumello D, Caironi P. et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes?. Intensive Care Med 2020; DOI: 10.1007/s00134-020-06033-2.
- 26 Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA 2020; DOI: 10.1001/jama.2020.6825.
- 27 Smith MJ, Hayward SA, Innes SM, Miller ASC. Point-of-care lung ultrasound in patients with COVID-19 – a narrative review. Anaesthesia 2020; DOI: 10.1111/anae.15082.
- 28 World Health Organisation. “Solidarity” Clinical Trial for COVID-19 Treatments. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global- research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19- treatments. Published 2020. Accessed May 9, 2020
- 29 World Health Organisation. 2019 Novel Coronavirus: A Coordinated Global Research Roadmap to Respond to TheD-19 Epidemic. Available at: https://www.who.int/blueprint/priority-diseases/key-action/Roadmap-version- FINAL-for-WEB.pdf?ua=1. Accessed June 6, 2020
- 30 Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMe2009758.